IHE presents at DIA Europe 2026

DIA Europe 2026 brought together regulators, industry leaders, researchers, patient representatives, and policy makers to explore the future of health care innovation in Europe. The program highlighted practical solutions to improve efficiency, transparency, and long-term resilience of health systems.

Andrea Manzano presented the poster “Immunotherapy and the Transformation of Cancer Care in Europe: Progress, Impact, and Gaps” and presented on how cancer survival in Europe has improved in recent decades, driven by medical innovation, earlier detection, more accurate diagnosis, better treatments, and coordinated national cancer control programs. A key driver in the last 15 years has been the introduction of immunotherapy – particularly the Nobel Prize-winning immune checkpoint inhibitors (ICIs). These medicines help the body’s immune system recognize and attack cancer cells, and since 2011, 14 ICIs have been approved in Europe for nearly 100 different uses. While cancer cases continue to rise in Europe driven in large part by population aging, deaths have stabilized, showing the impact of better care. Spending on cancer care has increased but still represents only about 6–7% of total healthcare expenditure. But the uptake of ICIs in clinical practice varies widely across Europe.

Conference: DIA Europe 2026 collaborating for healthcare innovation
Place: Rotterdam, Netherlands
Date: March 24-26, 2026